Navigation Links
Nephros Completes Bridge Financing
Date:2/4/2013

RIVER EDGE, N.J., Feb. 4, 2013 /PRNewswire/ -- Nephros, Inc. (OTC Bulletin Board: NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters, today announced that the company has entered into a bridge loan and security agreement with Lambda Investors LLC, an affiliate of Wexford Capital LP and the company's largest shareholder.

On February 4, 2013, the company issued a six-month 12% senior secured note to Lambda Investors in the principal amount of $1,300,000.  The company expects that the proceeds from the note will allow it to fund its operations into May 2013.

Under the terms of the note, the company has undertaken to conduct a $3 million rights offering of common stock at an anticipated offering price of $0.60 per share.  All of the company's stockholders and warrantholders will be eligible to participate in the offering on a pro rata basis based upon their proportionate ownership of the company's common stock on a fully diluted basis.  The company expects to commence the offering in March 2013 following the filing of its Annual Report on Form 10-K.  The note requires the company to repay the bridge loan with the proceeds from the rights offering or any other financing transaction.  

In connection with the proposed rights offering, Nephros will file a registration statement on Form S-1, as may be amended, with the Securities and Exchange Commission (the "SEC").  The securities offered in the rights offering may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective.  This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities, in any state in which such offer, solicitation or sale would be unlawful prior to their registration or qualification under the securities laws of any such state. 

Forward-Looking Statements
This press release contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended (the "PSLRA"). Such statements include statements regarding the efficacy and intended use of our technologies under development, the timelines for bringing such products to market and the availability of funding sources for the continued development of such products and other statements that are not historical facts, including statements which may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. For such statements, we claim the protection of the PSLRA. Forward-looking statements are not guarantees of future performance are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond our control. Actual results may differ materially from the expectations contained in the forward-looking statements. Factors that may cause such differences include, but are not limited to, the risks that:

  • we may not be able to continue as a going concern;
  • a default under the terms of the secured note would result in the lender foreclosing upon substantially all of our assets and could result in our inability to continue business operations;
  • we may not be able to complete the rights offering which could result in our inability to continue business operations;
  • even if we are able to complete the rights offering, we may not have sufficient capital to successfully implement our business plan;
  • restrictions in the secured note and related security agreement which require the prior consent of the lender may restrict our ability to operate our business, sell the company or sell our assets;
  • we may not be able to effectively market our products;
  • we may not be able to sell our water filtration products or chronic renal failure therapy products at competitive prices or profitably;
  • we may encounter problems with our suppliers and manufacturers;
  • we may encounter unanticipated internal control deficiencies or weaknesses or ineffective disclosure controls and procedures;
  • we may not obtain appropriate or necessary regulatory approvals to achieve our business plan;
  • products that appeared promising to us in research or clinical trials may not demonstrate anticipated efficacy, safety or cost savings in subsequent pre-clinical or clinical trials;
  • we may not be able to secure or enforce adequate legal protection, including patent protection, for our products; and
  • we may not be able to achieve sales growth in key geographic markets.

More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements, including the forward-looking statements in this press release, is set forth in our filings with the SEC. We urge investors and security holders to read those documents free of charge at the SEC's web site at www.sec.gov. We do not undertake to publicly update or revise our forward-looking statements as a result of new information, future events or otherwise, except as required by law.

 

 

     

 


'/>"/>
SOURCE Nephros, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Nephros and Chem-Aqua Announce Distribution Agreement
2. Nephros Reports Third Quarter 2012 Financial Results
3. Nephros Reports Second Quarter 2012 Financial Results
4. Nephros Reports First Quarter 2012 Financial Results
5. Nephros Receives 510(k) Clearance for Hemodiafiltration System
6. Nephros Appoints John C. Houghton as President and Chief Executive Officer
7. Valeant Completes Acquisition Of Natur Produkt In Russia
8. Linden Capital Partners Completes Acquisition of Young Innovations, Inc.
9. Flexpoint Completes Certification for Pressure Relief Device
10. Insero Health Completes Phase I Trial of Novel Therapy in Patients With Drug Resistant Epilepsy
11. Valeant Completes Acquisition of Medicis and Announces Date of 2013 Financial Guidance Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... 2016 Indiso ltd ... ungedeckten medizinischen Bedarf bei Lungen- und Atemwegserkrankungen ... Forschungsprogramms bekannt. Das Programm, das sich mit ... respiratorischen Funktionen und anderer klinischer Parameter. ... das sich auf den ungedeckten medizinischen Bedarf ...
(Date:2/11/2016)... - Cardiac Marker Diagnostic ... and Cancer Therapy. - European Point of Care ... - Key Diagnostic Testing Markets. - Molecular ... Genetic Testing. - Molecular Diagnostics in Infectious Disease ... Diagnostic Products World Markets. - Point of Care ...
(Date:2/11/2016)... LONDON , Feb. 11, 2016 Stem ... that are characterized by self-renewal and the capacity to ... a relatively new discovery, as the first mouse embryonic ... it was not until 1995 that the first culturing ... pluripotent stem cells were not produced until 2006 As ...
Breaking Medicine Technology:
(Date:2/13/2016)... ... 13, 2016 , ... The National Association for Children of ... representing the growing community of recovering individuals (now over 23 million), to issue ... policies addressing addiction. , Although many of the presidential candidates of both ...
(Date:2/13/2016)... FL (PRWEB) , ... February 13, 2016 , ... The ... environmental impact of American businesses. , The increasingly modern world of instantaneous consumption ... often on non-renewable energy sources such as oil and coal, which pollutes our air, ...
(Date:2/13/2016)... ... ... Au Pair comes all the way around the world to provide child care ... often worried things won’t go well. More often than not, however, they find out their ... Year winner’s all commented how their Au Pairs have become a part of the family, ...
(Date:2/12/2016)... ... February 12, 2016 , ... According to an article published ... for a significant portion of hernia repairs throughout the United States. Commenting on this ... Center notes that this trend has not only been expected, but it seems to ...
(Date:2/12/2016)... Seattle, WA, and Washington, DC (PRWEB) , ... ... ... PATH and the Siemens Foundation today announced a new initiative—the Siemens ... technologies for low-resource settings. The partnership will recruit top students from U.S. ...
Breaking Medicine News(10 mins):